Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists for Treatment of Obstructive Sleep Apnea: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Objective: To review and synthesize the current literature of clinical trials that investigated the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in people with obstructive sleep apnea (OSA). Method: MEDLINE, EMBASE, Cochrane Library, and PsycINFO were searched for randomized controlled trials (RCTs) in which GLP-1RAs were used to treat people diagnosed with OSA. This systematic review and meta-analysis complied with PRISMA 2020 guidelines and was registered on PROSPERO (CRD42024537280). A random effects model was used for meta-analysis to assess changes in OSA as measured by the apnea–hypopnea index (AHI) compared to continuous positive airway pressure (CPAP) or placebo controls. The standardized mean difference (SMD) and risk ratio (RR) were computed for continuous and binary outcomes. Variability between studies, risk of bias, subgroup analysis, and leave-one-out analysis were completed. Results: Five studies were included (N = 1023; 511 GLP-1RA and 512 control). Two trials used tirzepatide and four studies used liraglutide as the GLP-1RA. Six studies showed a decrease in AHI with an SMD of −14.5 events per hour (95%CI = −24.73 to −4.21; I2 = 96.3%). When compared to placebo, GLP-1RA treatment had a significant reduction in AHI (SMD = −0.69; 95%CI = −1.10 to −0.26; p = 0.001; I2 = 88.0%). When compared to CPAP, no significant difference in the reduction of AHI was found. No evidence of publication bias was found. Compared to control, there was no significant difference in serious adverse events (RR = 0.89; 95%CI = 0.50 to 1.57; p = 0.68; I2 = 20.93%). Conclusions: People with psychiatric disorders may also experience comorbid OSA that can impact their quality of life, which may perpetuate psychiatric symptoms of depression. GLP-1RAs may provide therapeutic potential in the treatment of OSA in addition to their cardioprotective effects. Current studies are limited by small sample sizes, lack of blinding, and short duration. Future studies will require further investigation in long-term efficacy and safety.